ILK and triple-negative breast carcinoma: For example, an unbiased genome-wide CRISPR-Cas 9 screen in triple-negative breast cancer revealed that loss of ILK and its binding partners α-parvin and PINCH-1 potentiated the inhibitory effect of bosutinib, a SRC/ABL kinase inhibitor [52].